coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    East Grinstead PCN, Mid Sussex · Health Inequalities Profile

    PCN U80779 · NHS Surrey and Sussex Integrated Care Board; NHS Sussex Integrated Care Board · 2 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    45,769

    Registered population

    56.6% aged 18–64

    24.0%

    Aged 65+

    ICB 21.9% · England 17.9%

    7.8%

    Ethnic minority (non-White)

    3.8% Asian · England 9.6%

    0.0%

    In IMD quintile 1

    ICB 9.2% · England 21.0%

    0

    Core20 residents (est.)

    Resident basis; registered basis 0 · see page 3

    8,677

    Hypertension register

    +6.76% in 3 yrs · England +5.60%

    408

    SMI register

    29.5% of Mid Sussex's

    832

    COPD register

    Reviews +24.79% in 3 yrs

    Forecast to 2030

    9,884

    Hypertension patients, 2030

    +1,207 on today

    75.1%

    QRISK ≥20% on statins, 2030

    +6.00pp over 3 yrs

    6.9%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    65.4%
    Under-80 BP and high-risk lipid therapy lag.

    Under-80 blood pressure control is 65.4% (England 67.8%; 3-year change -0.8% vs +3.2%) and high-risk lipid therapy is 61.0% (England 63.6%).

    6.4 pp
    Age-five MMR2 and pre-school booster below target.

    Age-five MMR drops 6.4 pp from dose 1 (95.4%) to dose 2 (89.0%), and the 4-in-1 booster is 88.1% against the 95.0% target.

    93.3%
    Recent BP recording and chronic reviews exceed England.

    Recent blood pressure recording reaches 93.3% (England 90.0%), with 80+ control at 81.4% (England 81.2%) and COPD annual reviews at 84.4% (England 76.4%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older patients aged 65+ make up 24.0% of the PCN, exceeding England's 17.9%

    Across 45,769 registered patients, 24.0% (11,004) are aged 65+, compared with 20.0% in Mid Sussex, 21.9% in NHS Sussex Integrated Care Board, and 17.9% in England. Across practices, Modality Mid Sussex has 27,615 patients with 25.0% aged 65+, while Moatfield Surgery has 18,154 patients with 22.6%. Resident Census data shows 92.2% White ethnicity (Mid Sussex 92.3%, ICB 91.0%, England 81.1%) and a 7.8% ethnic minority share, including 3.8% Asian or Asian British (Mid Sussex 3.6%, ICB 3.7%, England 9.6%). Census resident bases differ from registered lists.

    Age profile

    0–1719.4%
    18–6456.6%
    65+24.0%

    65+: ICB 21.9%, England 17.9%

    Ethnicity

    White92.2%
    Asian3.8%
    Mixed2.4%
    Black0.9%
    Other0.7%

    Older people · falls rows are Mid Sussex local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Mid Sussex LA)2,4942,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)90.4%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)59.8%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Mid Sussex LA)1,1849819552024/25
    Falls deaths, all ages, per 100,000 (Mid Sussex LA)13.714.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Average IMD decile is 8.3 with zero registered patients in Core20 deciles

    East Grinstead PCN has an average IMD decile of 8.3, matching Mid Sussex (8.3) and above NHS Sussex Integrated Care Board (6.1) and England (5.5). For Modality Mid Sussex (0.0%) and Moatfield Surgery (0.0%), 0.0% of registered patients live in Core20 areas (ICB 9.2%, England 21.0%). All 48 associated LSOAs sit above decile 2, giving 0 estimated Core20 residents. With zero Core20 concentration, inequalities work could focus on clinical inclusion cohorts rather than area indices.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Modality Mid0.0% · 0 patients
    Moatfield0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    408

    SMI register

    0.88% recorded prevalence

    246

    Learning disability register

    0.53% recorded prevalence

    27

    Care homes, 798 beds

    In the PCN catchment

    7.9%

    Provide unpaid care

    Mid Sussex, Census 2021

    The PCN records 408 severe mental illness patients (0.9% vs Mid Sussex 0.8%, ICB 1.1%, England 1.0%) and 246 learning disability patients (0.5% vs Mid Sussex 0.4%, ICB 0.6%, England 0.6%), alongside 27 catchment care homes (798 beds); catchment capacity does not establish resident counts. Crude recorded prevalence does not establish under-detection or unmet need, and care home bed capacity does not establish registered resident numbers.

    Severe mental illness: physical health checks

    Recorded SMI prevalence is 0.9% (408 patients). Captured checks show 87.3% had blood pressure recorded, 91.4% BMI and 85.8% alcohol. Smoking cessation offers fell 0.9 pp over three years (England +0.1 pp); uncaptured checks cannot imply complete reviews.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    8,677

    Hypertension register

    +6.76%

    Register growth, 3 yrs

    Mid Sussex +5.64% · England +5.60%

    −0.56pp

    BP control, under 80

    ≤140/90 · +6.27pp aged 80+

    +1,207

    More patients by 2030

    Forecast 9,884 (21.36%)

    Hypertension case-finding and control

    Hypertension register prevalence is 18.7% (8,677 patients), above Mid Sussex (16.1%) and England (15.2%). Recent blood pressure recording reaches 93.3% (England 90.0%). While control in patients aged 80+ is 81.4% (England 81.2%), control in under-80s is 65.4%, below Mid Sussex (67.9%) and England (67.8%), having fallen 0.8% over three years (England +3.2%). Under-80 control is 64.9% at Modality Mid Sussex and 66.4% at Moatfield Surgery; denominators include personalised care adjustments. Under-80 blood pressure control trails national rates despite high measurement coverage, which may reflect titration or adherence gaps to test via recall audit.

    Lipids and statins

    For high-risk cardiovascular prevention, lipid-lowering therapy reaches 61.0% in patients with QRISK ≥ 20% (England 63.6%) and 66.8% in CKD (England 70.3%). Secondary prevention statin treatment in diabetes with CVD is 79.5%, trailing England (84.4%). Structured statin initiation audits could address these treatment gaps.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202669,478£2.20£2.42£1.86£152,852
    Cardiovascular (all), 202596,391£3.67£3.32£3.33£353,755

    In 2026, 69,478 items of lipid-regulating drugs cost £2.20 per item (England £1.86; NHS Sussex Integrated Care Board £2.42). Spend was £23,623 more than at England's unit cost, but £15,285 less than at NHS Sussex Integrated Care Board's unit cost. Unit cost differences reflect local formulary choices and do not establish prescribing inefficiency.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +24.57%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +3.19%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 7.3% (3,197 patients; England 6.6%). Annual reviews grew +24.6% over three years (England +4.4%) to 68.6% (England 65.7%), leaving about 1,000 unreviewed patients; Modality Mid Sussex reached 58.6% and Moatfield Surgery 83.1%. COPD prevalence is 1.8% (832 patients; England 1.9%), with reviews rising +24.8% over three years (England +2.8%) to 84.4% (England 76.4%). Paediatric asthma prescribing is 1,021 rate per 1,000 (England 1,488 rate). Prioritising asthma review recall at Modality Mid Sussex could address unreviewed cases.

    Cancer register and children's immunisation

    Cancer register prevalence is 5.4% (2,493 patients; England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage at 12 months is 97.5% (England 91.0%), and MMR dose 1 at 24 months is 88.8% (England 88.3%). At age 5, a 6.4 pp gap separates MMR dose 1 (95.4%) and dose 2 (89.0%, below the 95.0% target by 6 pp). Pre-school 4-in-1 booster reaches 88.1% (target 95.0%). Second-dose pre-school recall is the key operational priority.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months97.5%

    England 91.0%

    6-in-1 complete primary course at 24 months93.3%

    England 92.2%

    MMR dose 1 at 24 months88.8%

    England 88.3%

    MMR dose 2 at age 589.0%

    England 82.8%

    4-in-1 pre-school booster at age 588.1%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    58.5%

    Sussex ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,360

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Sussex ICBEnglandNo usable stageStaged cancers
    Prostate56.6%53.2%19%1,668
    Breast86.1%85.4%23%1,400
    Bowel49.8%47.0%26%1,133
    Lung30.3%33.8%15%1,058
    Skin cancer95.3%87.8%17%698

    Across NHS Sussex ICB in 2022, 58.5% of staged cancers were detected at stage 1 or 2 (4,799 of 8,209), above England (55.3%) but below the 75.0% national ambition by 2028 by 16.5 pp. Staged cancers represented 64.3% of 12,766 registered ICB cancers (England 67.0%), requiring about 1,360 additional early diagnoses ICB-wide annually. Early detection was lowest in oesophagus (24.1%) and lung (30.3%). While ICB staging reflects wider system pathways, PCN cervical screening is 72.3%, ranging from 69.6% at Modality Mid Sussex to 76.4% at Moatfield Surgery.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026, Surrey and Sussex Healthcare NHS Trust achieved 70.0% on the 62-day cancer standard, below the 85.0% target by 15.0 pp, while University Hospitals Sussex NHS Foundation Trust reached 65.2%, Maidstone and Tunbridge Wells NHS Trust 87.4%, NHS Surrey and Sussex Integrated Care Board 71.5%, and England 71.2%. The trust met the 28-day faster diagnosis standard at 77.7% and the 31-day combined standard at 96.2%. Diagnostic waits include 28.5% of patients waiting 6+ weeks across all tests at Surrey and Sussex Healthcare NHS Trust (England 23.1%), including 43.8% for echocardiography and 32.3% for non-obstetric ultrasound.

    Pathways within standard (%)Surrey and Sussex HealthcareSussexMaidstone and Tunbridge WellsSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)77.7474.0181.7879.2979.32
    31-day treatment (96%)96.2076.7998.3590.4592.50
    62-day referral to treatment (85%)69.9765.2087.4371.5171.16
    Diagnostic waits over 6 weeks (%)Surrey and Sussex HealthcareSussexMaidstone and Tunbridge WellsEngland
    MRI27.535.620.9221.40
    CT18.498.570.519.92
    Echocardiography43.780.392.5728.48
    Colonoscopy15.1139.3519.8030.83
    Gastroscopy21.0620.0224.0329.02
    All 15 DM01 tests28.5012.956.4223.14
    Community services activityWest Sussex residentsSurrey and Sussex ICB
    Care contacts78,050309,615
    Referrals16,01566,930
    Patients with a contact19,77085,660

    Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026, West Sussex recorded 78,050 community care contacts across 19,770 patients, alongside 16,015 referrals. Across NHS Surrey and Sussex Integrated Care Board, 309,615 contacts were recorded for 85,660 patients. Adults aged 65+ accounted for 72.7% of West Sussex residents' contacts (56,740). These experimental data describe local authority and ICB activity rather than PCN caseloads.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Easy phone access spans 21.0% to 51.9% across the PCN's two practices

    In 2025/26, overall QOF achievement was 95.2% at Moatfield Surgery against an England average of 92.5%, whereas Modality Mid Sussex achieved 89.7%. Clinical achievement reached 100.0% at Moatfield Surgery (England 97.1%), while Modality Mid Sussex reached 96.5%. Vaccination and immunisation achievement diverged by 20.8 pp: Moatfield Surgery achieved 57.4% (England 55.2%), compared with 36.6% at Modality Mid Sussex.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Moatfield Surgery1010.051.9%69.8%79.9%
    Modality Mid1040.021.0%48.3%51.4%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNMid SussexAssetPCNMid Sussex
    Care homes (catchment)27 (798 beds)n/aSchools (catchment)54n/a
    Children's centres68Places of worship4695
    Libraries14Homelessness support (VCS)0no data
    Day centres (VCS)n/a2Carers support groups (VCS)n/a1
    Primary schools (LA maintained)1519Primary academies1022
    Special schools21

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Asthma annual review recall audit

    Across 3,197 asthma patients, annual review coverage is 68.6% (Mid Sussex 66.3%; England 65.7%), leaving about 1,000 (1,004) patients without a recorded review. For discussion: run a structured asthma review recall using a common template, starting at Modality Mid Sussex where recorded review coverage is 58.6%. Low cost, quick to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Under-80 hypertension and lipid review

    Across 8,677 hypertension patients, under-80 BP control is 65.4% (Mid Sussex 67.9%; England 67.8%; 3-year change -0.8% vs England +3.2%), while QRISK >= 20% lipid therapy is 61.0% (England 63.6%). Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Pre-school booster and MMR2 recall

    In Q1 2025/26 (cohort 109), age-five MMR dose 2 is 89.0% (below the 95.0% target by 6 pp and 6.4 pp below dose 1 at 95.4%), with 4-in-1 booster at 88.1%. For discussion: audit age-five cohorts for missing second MMR and 4-in-1 booster doses and test flexible clinic times. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Inclusion health clinical targeting (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Smoking cessation support review (p4)Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension control recall audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school second dose recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening review (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Telephony and access triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Asthma annual review recall audit (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN & Practice
    Option 2 · Under-80 hypertension and lipid review (p12)Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapyCore20PLUS5 CVD · CVDPREVENT 2029PCN & Practice
    Option 3 · Pre-school booster and MMR2 recall (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN & Practice
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15